Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Carnival

ChargePoint Holdings

Chewy

NVIDIA

Ocugen, Inc.

Shopify

These stocks to sell have stretched valuation, but their fundamentals are robust and these stocks are worth accumulating on a correction. The post 7 Stocks to Sell as You Head Into July 2021 appeared first on InvestorPlace.

7 Stocks to Sell as You Head Into July 2021

Its fast-growing platform is entrenched in physicians' workflows, and it's already turning a profit.

Forget Meme Stocks and Cryptocurrency: This Healthcare IPO Could Make You Richer

Some 10,000 physicians in its network are betting an average of $24,000 apiece on Doximity stock. If it can sustain expectations-beating growth, those MDs are making a smart bet.

After Popping 115% Since Its IPO, Doximity Stock Could Keep Rising

Does Doximity Belong on Your Watch List?

As the LinkedIn for doctors, Doximity has massive potential to be a dominant player in the telehealth market. Its main value proposition is its network of medical professionals. Teladoc's struggle is Doximity's opportunity.

Doximity: Potential Teladoc Killer

Doximity CEO Jeff Tangney became the latest tech billionaire this week after taking Doximity public on the New York Stock Exchange.

Doximity CEO ignored Silicon Valley wisdom and built a $10 billion health-tech company

16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity, which soared 104% in its debut. The week's IPOs were joined by four SPACs, as well as one postponement, Chinese social networking platform Soulgate.

U.S. IPO Weekly Recap: Doximity Pops More Than 100% In A 16 IPO Week

Doximity (DOCS) stock is retreating on Friday after the company saw its shares rocket higher with its initial public offering (IPO). The post Doximity IPO: 16 Things to Know About DOCS Stock After Its 103% Debut appeared first on InvestorPlace.

Doximity IPO: 16 Things to Know About DOCS Stock After Its 103% Debut

Healthcare technology platform Doximity Inc. and an investor raised $606 million after pricing an initial public offering above the marketed range, according to a company statement. Doximity was originally shooting for a $100 million initial public offering (IPO) in its May 28 filing with the Securities and Exchange Commission for the ticker symbol DOCS.

Doximity Blows Away IPO Goal On First Day Of NYSE Trading

Confluent

Benchmark and Index Ventures are the biggest winners from Confluent's IPO, while Emergence Capital and InterWest Partners are the top investors in Doximity.

Four Silicon Valley VC firms notched billion-dollar IPO wins on Thursday

Doximity, an 11-year old online network for medical professionals, went public after increasing revenue 77% in the latest fiscal year to over $200 million.

Doximity surges 69% in NYSE debut after IPO values health-tech company at $4.6 billion

Monte Rosa Therapeutics

Grove

Bright Health Group

Miromatrix Medical Inc

The IPO tidal wave continued Thursday, with a mix of healthcare and technology startups making their trading debut.

6 Companies Are Making Their Trading Debuts. What Investors Need to Know.

Doximity, Inc (NYSE: DOCS) priced 23.3 million shares at $26 per share in its initial public offering, for estimated gross proceeds are $494.3 million.   The healthcare platform previously marketed the IPO at the range of $20 - $23, Bloomberg reports.

HealthCare Provider Doximity Prices Upsized IPO At $26/Share; Trading Begins Today

SAN FRANCISCO, June 23, 2021 /PRNewswire/ -- Doximity, Inc. ("Doximity") (NYSE: DOCS) today announced the pricing of its initial public offering of 23,300,000 shares of its Class A common stock at a price to the public of $26.00 per share. The offering consists of 19,010,750 shares of Class A common stock being sold by Doximity and 4,289,250 shares of Class A common stock being sold by an existing stockholder.

News for Doximity Stock (DOCS)